NPT
IRD

Nixon Peabody Trust’s Opus Genetics IRD Stock Holding History

Nixon Peabody Trust’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-21
Closed -$5K – 67
2017
Q1 		$5K Hold
21
– – ﹤0.01% 64
2016
Q4 		$1K Hold
21
– – ﹤0.01% 65
2016
Q3 		$2K Hold
21
– – ﹤0.01% 68
2016
Q2 		$3K Hold
21
– – ﹤0.01% 85
2016
Q1 		$3K Hold
21
– – ﹤0.01% 84
2015
Q4 		$4K Buy
+21
New +$4.47K ﹤0.01% 84

Other funds holding IRD

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
HVIA
Hudson Valley Investment Advisors Goshen, New York $823M AUM 31.4% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return

Nixon Peabody Trust's IRD Position: Q2 2017 in Review

Nixon Peabody Trust sold out of Opus Genetics (IRD) in Q2 2017, closing a stake of 21 shares — an estimated $5K sold.

Nixon Peabody Trust first reported a position in IRD in Q4 2015 and held it in 6 quarters. The position peaked at $5K in Q1 2017. 23 funds tracked by Wall St. Rank hold IRD as of Q2 2017.

  • Nixon Peabody Trust reported no remaining Opus Genetics position as of Q2 2017 after selling out during the quarter.
  • Nixon Peabody Trust sold 21 Opus Genetics shares in Q2 2017, an estimated $5K.
  • Nixon Peabody Trust first reported a position in Opus Genetics in Q4 2015 and held it in 6 quarters.
  • Nixon Peabody Trust's Opus Genetics position peaked at $5K in Q1 2017.
  • 23 funds tracked by Wall St. Rank held Opus Genetics as of Q2 2017.

Based on Nixon Peabody Trust's 13F filing for Q2 2017, filed 17 Jul 2017.